How this Houston-headquartered company is innovating the future of heart replacement

HOUSTON INNOVATORS PODCAST EPISODE 183

Thomas Vassiliades, CEO of BiVACOR, joins the Houston Innovators Podcast. Photo courtesy of BiVACOR

Heart disease is one of the most common causes of death in the United States — one in five deaths, according to the CDC. But there's not a long-term solutions for patients — even for those lucky enough to have a successful heart transplant. But a Houston-headquartered medical device company is working on one.

BiVACOR has created a technology that, theoretically, could completely replace a patient's heart and last them the rest of their lives.

"The design is critical," says Thomas Vassiliades, CEO of BiVACOR, on the Houston Innovators Podcast. He joined the organization last year after spending 20 years of a heart surgeon, then transitioning to medical device development over a decade ago.

Vassiliades explains the industry's challenges on the show, saying that there's no comprehensive, lasting replacement to the human heart on the market. While some treatments — like transplants and medical devices that partially replace the heart's capabilities — exist, nothing that completely replaces the heart lasts longer than 10 to 12 years.

"The BiVACOR system is based on magnetic levitation," Vassiliades says about the technology. "Our pump is just one moving impeller that sits in the middle of the housing where the blood is. Imagine an artificial heart — the container that has your blood — and the device spinning in the inside — basically a wheel spinning your blood to the rest of your body.

"The device is suspended by magnets — it's not touching anything," he continues. "So, theoretically, the device has no wear and can last as long as the patient can possibly live. That's new to the field."

Daniel Timms, BiVACOR's founder and CTO, knew there had to be a better, more permanent solution and has been working on the technology since he was a postdoctoral student at Queensland University of Technology in Australia. His work took him to Houston's Texas Heart Institute, the "center of the universe when it comes to blood pumps," says Vassiliades.

The company recently raised $18 million in funding to support its growing team and continued growth. BiVACOR is a Class 3 medical device — the most rigorously regulated type of device, so the funding raised will support the company as it continues to meet the FDA's requirements and proceeds into implantation and clinical trials.

While headquartered in Houston and has close ties to THI, most of BiVACOR's team works out of Huntington Beach, California, just 30 minutes away from its manufacturing partner — something that has been critical for the design phase. Other employees work in Europe and Australia, which has resulted in government grant funding. Each market the company works in has a strategic purpose — and Houston's role is testing.

"We're going to be training all our clinical sites in Houston, and we're going to continue to do ongoing testing," he says. "We're very comfortable with the design of the device, ... but there's always more. And we have a long-term plan to iterate on the device to make it even better."

Vassiliades shares more of the challenges he's facing as he commercializes BiVACOR's technology on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


From Your Site Articles
BiVACOR named Thomas Vassiliades as CEO effective immediately. Photo courtesy of BiVACOR

Former Medtronic exec takes the helm of Houston med device startup

mover and shaker

A Houston-based preclinical artificial heart device company has a new head honcho as it grows its team and further develops its technology.

BiVACOR named Thomas Vassiliades as CEO effective immediately. He replaces the company's founder, Daniel Timms, in the position. BiVACOR is on track to head toward human clinical trials and commercialization, and Vassiliades is tasked with leading the way.

“BiVACOR led an extensive CEO search, and Tom was the clear choice given his experience, background, leadership style, and exceptional track record,” says Timms in a news release. “Tom has the skillset and credibility to guide BiVACOR through its next chapter of transformation and advancement as we undertake the next stage of clinical activities leading up to First in Human early feasibility studies.”

Vassiliades has over 30 years of experience within the medical device industry as well as cardiothoracic surgery. He was most recently the general manager of the surgery and heart failure business at Abiomed and held several leadership roles at Medtronic. Dr. Vassiliades received his MD from the University of North Carolina, and his MBA was achieved with distinction at Emory University.

“I am excited and honored to join the BiVACOR team, working closely with Daniel and the entire team as we look forward to bringing this life-changing technology to the market,” says Dr. Vassiliades in the release. “Throughout my career, I’ve been guided by the goal of bringing innovative cardiovascular therapies to the market to improve patient care and outcomes – providing solutions for those that don’t have one. BiVACOR is uniquely well-positioned to provide long-term therapy for patients with severe biventricular heart failure.”

Timms will take over BiVACOR's technical team working on the Total Artificial Heart system as CTO. The device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

The medical device company, which has operations in Houston and Australia, recently announced the addition of eight new employees doubling their team. The growth comes following its series B raise last year.

“It is a testament to the great progress the team has made and to the importance of the unmet clinical need addressed by the Total artificial Heart technology," Timms says on the appointment of Vassiliades. "We look forward to Tom’s leadership as BiVACOR navigates the path to commercialization.”

In the latest round up of Houston innovation news you may have missed, a health tech startup has grown its team, a coworking company opens its latest location, and more. Shobeir Ansar/Getty Images

Houston named a top market for remote tech workers, startup doubles its staff, and more innovation news

short stories

Houston is starting 2022 strong in terms of innovation news, and there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, the Bayou City is ranked based on its ability to employ remote tech talent, a coworking company opens a new location, a med device startup doubles its staff, and more.

New report finds Houston a top market for remote tech talent

Houston is a top city for employing remote tech workers. Graphic via Karat

In a new report, Karat — a Seattle-based human resources company — looked at which metros were best for attracting remote tech talent. The company first completed the report based on 2020 due to a changing workforce spurred by the pandemic.

"Last year we took our first look at the rapidly expanding remote software engineer hiring landscape. As more organizations shifted to remote or hybrid working models we had started to see significantly improving candidate performance outside of the more-established tech hubs," writes Patrick Wu, data analyst at Karat, in a blog post. "Today, as even more top tech companies commit to hiring remote software engineers, we’re taking a look at how this landscape has continued to evolve."

Houston ranked No. 6 this year in the list of 10 metros just ahead of No. 7 Austin. Last year, Houston ranked as No. 2 and Dallas at No. 9, but that North Texas metro fell off the top 10 for 2021. Pittsburgh maintained its top spot on this list year over year.

Houston artificial heart company makes strategic hires

This med device company has eight new team members. Photo via bivacor.com

BiVACOR, a Houston-based cardiatric medical device company, announced that it has doubled the size of its team with the addition of eight team members. The growth comes following its series B raise last year.

“The diversity of skills and experience throughout the company is something we are very proud of, and I am pleased to welcome this all-star group of individuals to the team,” says Daniel Timms, BiVACOR founder and CEO, in a December news release. “They will each play an integral role in the overall accomplishments of BiVACOR, specifically as we undertake benchtop and preclinical verification activities so that we can commence our First in Human early feasibility study in the near future.”

Here's who recently joined the company at both its United States and Australia-based operations:

  • Nathan Kong, purchasing administrator
  • Farhad Akhavan, systems engineer
  • David Duarte, verification and validation engineer
  • Paul Chiver, manufacturing technician
  • Lindsey Brede, financial controller
  • Dawnel Scott, director QA/RA
  • Mairi Maclean, director of product development
  • Nicole Bartnikowski, scientific manager (Australia)

“Having the ability to attract and hire individuals with the industry knowledge and pedigrees of this world-class team is a testament to how BiVACOR is perceived in the industry," Timms continues. "Each of them brings a unique perspective and skillset to BiVACOR and will play an important role in furthering our technology.”

BiVACOR is developing its Total Artificial Heart, or TAH. The device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

Coworking company opens new Houston location

Common Desk has a new West Houston location. Photo via Common Desk

Dallas-based Common Desk has announced the opening of its newest location in Westchase District. The flexible workspace company opened its first location in Houston in October 2020 and unveiled four more locations since then. The company shares in a news release that two more spots will be opening in 2022.

Common Desk - Westchase (2500 CityWest Blvd) ha 20,000 square feet of coworking space with 54 private offices, four office suites, six conference rooms, and shared space. Tenants will have access to an outdoor space, reserved and unreserved garage parking, a fitness center, and Common Desk's coffee brand, Fiction Coffee.

"When thinking about expanding our reach in the city, we knew we wanted to be somewhere in West Houston,” says Bobby Spoden, community sales manager at Common Desk, in the release. “Community comes first at Common Desk, and we love that the Westchase District shares the same value. We couldn't be more excited and honored to become part of the rich community in the West Houston area, and we're looking forward to the new additions to our vibrant member base."

Houston fintech unicorn expands on partnership with software company

HighRadius has deepened its partnership with Genpact. Photo via highradius.com

New York-based Genpact and Houston-based HighRadius announced the expansion of their strategic partnership. The expanded partnerships means the merging HighRadius's Autonomous Software platform with Genpact’s global accounts receivables and digital process and delivery expertise to enhance client experience across the board.

“Now more than ever, the finance function plays a vital role in leading businesses through crises, providing agility and insight that lead to greater resilience. To thrive, organizations must connect, predict and adapt at speed, placing data at their core and embracing digital technologies,” says Tiger Tyagarajan, CEO at Genpact, in a news release. “Bringing our two companies together in even deeper partnership will allow a new level of predictive intelligence that can derive meaningful insights and lead to impactful action for our clients.”

The duo originally teamed up in February of 2020 to bring together their expertise — digital automation solutions and advanced machine learning and artificial intelligence.

“If we paint the picture of the future of finance, and therefore the future of the CFO and the CFO organization, we think about the world of the CFO as one where technologies will basically allow them to make decisions every minute,” says Sashi Narahari, founder and CEO at HighRadius, in the release. “Prediction is what the machine will do. Decision, judgment and experience are never going to go away from human beings. So, humans are going to spend more time than they do today on decisions and examining business outcomes. That’s where the HighRadius and Genpact partnership can make a big difference.”

3 deadlines approach for Houston startup opportunities

Don't miss these three founder opportunities. Photo via Rice

Three different entrepreneurial opportunities have deadlines quick approaching.

  • The Rice Business Plan Competition, which is planned for April 7-9 this year, has its applications open until January 31. Any graduate-student startup, in a broad range of industries, from any university, in any degree program, in any country, can apply to the RBPC. Learn more about the competition and how to apply online at https://rbpc.rice.edu/compete.
  • Applications are open for the Black Girl Ventures Change Agent Fellowship, a nine-month leadership skills development program for Black and Brown women entrepreneurs and ecosystem builders. Selected applicants, who must be based in Los Angeles, New York, Chicago, Miami, Houston or Detroit, will each receive a $10,000 stipend. The time commitment is about 8 hours/month. The deadline to apply is January 31, 2022, and decisions will be made by mid-February. Learn more and apply at https://www.blackgirlventures.org/fellowship.
  • The 2022 HCC Business Plan Competition has applications open through January 28. The BPC will begin in late February and run through early June, with six free, virtual, 1.5 hour training  sessions. To learn more about the program and eligibility, click here.

Through a series B round and a federal grant, BiVACOR has raised $22 million in funding ahead of human trials. Photo via bivacor.com

Houston-based artificial heart company snags $22M in fresh funds

money moves

Houston-based medtech company BiVACOR has picked up $22 million in funding — in the form of a series B round and a federal grant — to propel development of its Total Artificial Heart device for treatment of severe heart failure.

In a May 19 news release, BiVACOR says it received a series B round of $19 million and a National Institutes of Health grant of $3 million. Boston-based Cormorant Asset Management and Australia's OneVentures, through its OneVentures Healthcare Fund III, led the round.

OneVentures first invested in BiVACOR three years ago. According to Australia's Financial Review, OneVentures initially pumped $3 million (Australian dollars) into BiVACOR, with the potential of contributing as much as $10 million if BiVACOR met certain milestones. BiVACOR received a round of seed funding from U.S. investors in 2013.

"BiVACOR's one-of-a-kind technology is supported by a remarkable team that has moved this technology a significant distance toward the clinic," Paul Kelly, managing partner of OneVentures, says in BiVACOR's news release.

The fresh cash will support preparation for the first human trials of the device. As a short-term measure, the device can be implanted in someone awaiting a heart transplant. It's also designed to be a long-term alternative to a heart transplant.

The BiVACOR device, billed as the first long-term therapy for patients with severe heart failure, is an implantable artificial heart based on rotary blood-pump technology. Similar in size to an adult fist, it is small enough to be implanted in many women and some children yet capable of delivering enough cardiac power to a man who's exercising. Unlike the two-chamber human heart, BiVACOR's device features a single chamber.

"The commitment and interest from our investors validate our technology and the need for improved options to treat end-stage biventricular heart failure," says Daniel Timms, founder and CEO of BiVACOR. "With this financing, we will be able to expand our world-class team and undertake … verification activities so that we can commence our first-in-human early feasibility study in the near future."

Founded in 2008, BiVACOR maintains offices in Cerritos, California, and Brisbane, Australia. The company is affiliated with Houston's Texas Heart Institute, where the world's first artificial heart was implanted. BiVACOR's headquarters is at the Texas Medical Center complex.

The company employs about a dozen people and says the funding will enable it to bring on another 10 employees.

For 13 years, BiVACOR has been working on technology aimed at eliminating the need for heart transplants. Thus far, the BiVACOR device has been tested only on cows.

"In heart failure, the heart becomes unable to pump enough blood to keep the body healthy and strong. At least 26 million people around the world are living with the disease, and the number is rising as populations age," IEEE Spectrumreported in 2019. "Patients with severe heart failure have a bleak outlook: Their best option is a heart transplant, but the limited number of donor hearts means that only about 5,000 patients around the world receive transplants each year. Thousands more patients are eligible for transplants, and some die while waiting for a donor organ."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston innovators who made headlines in May 2025

Innovators to Know

Editor's note: Houston innovators are making waves this month with revolutionary VC funding, big steps towards humanoid robotics, and software that is impacting the agriculture sector. Here are three Houston innovators to know right now.

Zach Ellis, founder and partner of South Loop Ventures

Zach Ellis. Photo via LinkedIn

Zach Ellis Jr., founder and general partner of South Loop Ventures, says the firm wants to address the "billion-dollar blind spot" of inequitable distribution of venture capital to underrepresented founders of color. The Houston-based firm recently closed its debut fund for more than $21 million. Learn more.

Ty Audronis, CEO and founder of Tempest Droneworx

Ty Audronis, CEO and founder of Tempest Droneworx

Ty Audronis, center. Photo via LinkedIn.

Ty Audronis and his company, Tempest Droneworx, made a splash at SXSW Interactive 2025, winning the Best Speed Pitch award at the annual festival. The company is known for it flagship product, Harbinger, a software solution that agnostically gathers data at virtually any scale and presents that data in easy-to-understand visualizations using a video game engine. Audronis says his company won based on its merits and the impact it’s making and will make on the world, beginning with agriculture. Learn more.

Nicolaus Radford, CEO of Persona AI

Nicolaus Radford, founder and CEO of Nauticus RoboticsNicolaus Radford. Image via LinkedIn

Houston-based Persona AI and CEO Nicolaus Radford continue to make steps toward deploying a rugged humanoid robot, and with that comes the expansion of its operations at Houston's Ion. Radford and company will establish a state-of-the-art development center in the prominent corner suite on the first floor of the building, with the expansion slated to begin in June. “We chose the Ion because it’s more than just a building — it’s a thriving innovation ecosystem,” Radford says. Learn more.

Pharmaceutical giant plans $5.9B Houston facility and more news to know

Trending News

Editor's note: It's time to look back at the top Houston innovation news from the second half of May 2025. From exciting VC raises to major manufacturing facilities in the works, here are the most-read InnovationMap stories from May 16-30.

1. Pharmaceutical giant looks to bring $5.9 billion facility to Houston

Eli Lilly is looking to build an active pharmaceutical ingredient manufacturing facility at Generation Park. Rendering courtesy of McCord

Pharmaceutical company Eli Lilly and Company is looking to build a $5.9 billion active pharmaceutical ingredient (API) manufacturing facility in Houston, according to a recent filing with the state of Texas.

The proposal states that the project plans to employ 604 full-time direct employees at the site upon ramp-up completion. Construction is projected to begin in 2026, with a completion target of 2030 and commercial operations beginning in 2031. Continue reading.

2. Houston VC firm closes $21M fund for underrepresented founders

Zach Ellis, founder and general partner of South Loop Ventures, which recently closed its debut fund. Photo via LinkedIn

Houston-based South Loop Ventures recently closed its debut fund for more than $21 million, led by investments from Rice Management Company and Chevron Technology Ventures.

The funds will go toward teams with at least one underrepresented founder of color working in the energy, health, space, sports and fintech sectors. Additional investments came from The Great Commission Foundation of the Episcopal Diocese of Texas, Texas CapitalBank and others organizations. Continue reading.

3. Houston-founded startup raises $1.2M and moves headquarters to Detroit

ChurchSpace, founded in Houston by Day Edwards and Emmanuel Brown, is moving to Detroit. Photo courtesy ChurchSpace.

Houston-founded ChurchSpace, known as the Airbnb for churches, has formed an official partnership with the City of Detroit and will relocate its headquarters.

The announcements come as the company successfully closed a $1.2 million oversubscribed funding round. The round was led by California-based Black Ops Ventures, with participation from Michigan Rise and Dug Song of Minor Capital, who is also the founder of the Song Foundation, another Michigan-based organization. Continue reading.

4. Houston aerospace co. soars with first U.S. test flight of hypersonic engine

Venus Aerospace successfully completed the flight test of its hypersonic engine, the first of an American-developed engine of its kind. Photo courtesy Venus Aerospace

Houston-based Venus Aerospace successfully completed the first U.S. flight test of its proprietary engine at a demonstration at Spaceport America in New Mexico.

Venus’ next-generation rotating detonation rocket engine (RDRE) is supported by a $155,908 federal Small Business Innovation Research (SBIR) grant from NASA and aims to enable vehicles to travel four to six times the speed of sound from a conventional runway. The recent flight test was the first of an American-developed engine of its kind. Continue reading.

5. Houston regenerative medicine company expands lab for future trials

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. With its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research. Continue reading.

Houston university to launch artificial intelligence major, one of first in nation

BS in AI

Rice University announced this month that it plans to introduce a Bachelor of Science in AI in the fall 2025 semester.

The new degree program will be part of the university's department of computer science in the George R. Brown School of Engineering and Computing and is one of only a few like it in the country. It aims to focus on "responsible and interdisciplinary approaches to AI," according to a news release from the university.

“We are in a moment of rapid transformation driven by AI, and Rice is committed to preparing students not just to participate in that future but to shape it responsibly,” Amy Dittmar, the Howard R. Hughes Provost and executive vice president for academic affairs, said in the release. “This new major builds on our strengths in computing and education and is a vital part of our broader vision to lead in ethical AI and deliver real-world solutions across health, sustainability and resilient communities.”

John Greiner, an assistant teaching professor of computer science in Rice's online Master of Computer Science program, will serve as the new program's director. Vicente Ordóñez-Román, an associate professor of computer science, was also instrumental in developing and approving the new major.

Until now, Rice students could study AI through elective courses and an advanced degree. The new bachelor's degree program opens up deeper learning opportunities to undergrads by blending traditional engineering and math requirements with other courses on ethics and philosophy as they relate to AI.

“With the major, we’re really setting out a curriculum that makes sense as a whole,” Greiner said in the release. “We are not simply taking a collection of courses that have been created already and putting a new wrapper around them. We’re actually creating a brand new curriculum. Most of the required courses are brand new courses designed for this major.”

Students in the program will also benefit from resources through Rice’s growing AI ecosystem, like the Ken Kennedy Institute, which focuses on AI solutions and ethical AI. The university also opened its new AI-focused "innovation factory," Rice Nexus, earlier this year.

“We have been building expertise in artificial intelligence,” Ordóñez-Román added in the release. “There are people working here on natural language processing, information retrieval systems for machine learning, more theoretical machine learning, quantum machine learning. We have a lot of expertise in these areas, and I think we’re trying to leverage that strength we’re building.”

View All Listings